

Status of the claims:

1. (Currently amended) A pharmaceutical composition comprising:
 - an effective amount of amlodipine;
 - an effective amount of hydroxylated atorvastatin metabolite; and
 - a pharmaceutically acceptable carrier or diluent,

wherein the effective amounts of amlodipine and hydroxylated atorvastatin metabolite ~~coordinated to substantially~~ synergistically inhibit lipid peroxidation in human low density lipoprotein or lipid membrane to achieve a therapeutic effect.
2. (Original) The pharmaceutical composition of claim 1 wherein the amlodipine is provided as an effective derivative of amlodipine.
3. (Original) The pharmaceutical composition of claim 2 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.
4. (Currently amended) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of reducing the risk of arterial and related heart disease.
5. (Original) The pharmaceutical composition of claim 4 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

6. (Currently amended) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid peroxidation ~~to the extent necessary to achieve the therapeutic effect of lowering blood pressure.~~

7- 28. (Canceled)

Claims 29-56 (Withdrawn)

57. (Currently amended) A pharmaceutical composition comprising:
an amount of amlodipine;
an amount of hydroxylated atorvastatin metabolite; and
a pharmaceutically effective carriers or diluents.

Claims 60-62 (Withdrawn)

63. (Currently amended) A pharmaceutical composition comprising:
an effective amount of amlodipine;
an effective amount of hydroxylated atorvastatin metabolite; and
a pharmaceutically acceptable carrier or diluent;
wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that ~~an~~ a synergistic antioxidant effect is achieved by ~~the combined amounts which is greater than the antioxidant effect of either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.~~

64. (Currently amended) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that ~~the~~ a synergistic inhibition of lipid peroxidation is achieved by the combined amounts is greater than the inhibition of lipid peroxidation achieved by either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.

65. (Currently amended) The pharmaceutical composition of claim 64 wherein said selection is further coordinated for achieving ~~an~~ a synergistic antioxidant effect, ~~which effect is greater than the antioxidant effect achieved by said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite independently.~~

66. (New) The pharmaceutical composition of claim 63, wherein said composition is used to treat atherosclerosis.

67. (New) The pharmaceuticals composition of claim 66, wherein said atherosclerosis involves diseases selected from the group consisting of myocardial infarction, stroke, transient ischemic attack, coronary heart disease and a combination thereof.

68. (New) The pharmaceutical composition of claim 63 further comprising an endogenous and/or exogenous antioxidant.